Galena’s NeuVax Mops Up Circulating Breast Cancer Cells To Prevent Metastases
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Median five-year data from the Phase I/II NeuVax trial released at ASCO this June showed that among node-positive patients 25.9% of the control had a recurrence, while metastases surfaced in only 5.6% of NeuVax patients. Final gold standard five-year data for all patients were released at the San Antonio Breast Cancer Symposium Dec. 5; Galena launched a Phase III trial in January 2012.
You may also be interested in...
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.